OTCMKTS:MEDIF MediPharm Labs (MEDIF) Stock Price, News & Analysis $0.05 0.00 (-5.42%) As of 08/8/2025 03:55 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About MediPharm Labs Stock (OTCMKTS:MEDIF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MediPharm Labs alerts:Sign Up Key Stats Today's Range$0.05▼$0.0550-Day Range$0.05▼$0.0752-Week Range$0.04▼$0.09Volume214,805 shsAverage Volume121,222 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MediPharm Labs Corp., a pharmaceutical company, engages in the production and sale of purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll cannabis products. In addition, the company offers cannabis related medical information and services; and medical cannabis clinic services. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada. Read More Receive MEDIF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediPharm Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address MEDIF Stock News HeadlinesMediPharm Labs Expands Leading CBN Oil Portfolio with The Launch of New Nighttime InhalerJuly 24, 2025 | globenewswire.comMediPharm Labs Corp.: MediPharm Announces Voting Results from the 2025 Annual and Special Meeting of ShareholdersJune 17, 2025 | finanznachrichten.deElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. | Brownstone Research (Ad)MediPharm Announces Voting Results from the 2025 Annual and Special Meeting of ShareholdersJune 17, 2025 | globenewswire.comMediPharm Cautions Shareholders To Await Final Results of Annual and Special MeetingJune 16, 2025 | globenewswire.comApollo Capital Wins Proxy Contest at MediPharm LabsJune 16, 2025 | globenewswire.comMedipharm announces Glass Lewis recommends shareholders vote for all nomineesJune 14, 2025 | finance.yahoo.comLeading Independent Proxy Advisor Glass Lewis Recommends Shareholders Vote the GREEN proxy FOR ALL MediPharm Director NomineesJune 13, 2025 | globenewswire.comSee More Headlines MEDIF Stock Analysis - Frequently Asked Questions How have MEDIF shares performed this year? MediPharm Labs' stock was trading at $0.0413 at the beginning of the year. Since then, MEDIF stock has increased by 22.5% and is now trading at $0.0506. How do I buy shares of MediPharm Labs? Shares of MEDIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:MEDIF CIKN/A Webwww.medipharmlabs.com Phone(705) 719-7425FaxN/AEmployees166Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (OTCMKTS:MEDIF) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredChina's 500 Million Year AdvantageThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediPharm Labs Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediPharm Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
